Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: a safety analysis of the FDA adverse event reporting system

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: 1 Online-Ressource.

Language: Englisch

Bibliographic citation: Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: a safety analysis of the FDA adverse event reporting system ; volume:25 ; number:1 ; day:23 ; month:2 ; year:2024 ; pages:1-9 ; date:12.2024
BMC pharmacology & toxicology ; 25, Heft 1 (23.2.2024), 1-9, 12.2024

Creator: Zhao, Dehua
Long, Xiaoqing
Wang, Jisheng

Contributor: SpringerLink (Online service)

DOI: 10.1186/s40360-024-00741-x

URN: urn:nbn:de:101:1-2404301309556.918026305647

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:59 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Zhao, Dehua
Long, Xiaoqing
Wang, Jisheng
SpringerLink (Online service)

Other Objects (12)

BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro

Hochschulschrift

Genomische BCR-ABL1-Bruchpunkte bei kindlichen Leukämien

The BCR::ABL1 tyrosine kinase inhibitors ponatinib and nilotinib differentially affect endothelial angiogenesis and signalling

BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene

FISH mapping of Philadelphia negative BCR/ABL1 positive CML

Approach to Diagnosis of BCR::ABL1-Negative Myeloproliferative Neoplasms

Targeting Poly(ADP)ribose polymerase in BCR/ABL1-positive cells

Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1

Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy

Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1T315I and BCR-ABL1T315I-E255K

Hochschulschrift

The role of proteostasis in BCR-ABL1-positive acute lymphoblastic leukemia

Hochschulschrift

Pre-B cell receptor signaling prevents malignant transformation by BCR-ABL1

BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro

Hochschulschrift

Genomische BCR-ABL1-Bruchpunkte bei kindlichen Leukämien

The BCR::ABL1 tyrosine kinase inhibitors ponatinib and nilotinib differentially affect endothelial angiogenesis and signalling

BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene

FISH mapping of Philadelphia negative BCR/ABL1 positive CML

Approach to Diagnosis of BCR::ABL1-Negative Myeloproliferative Neoplasms

Targeting Poly(ADP)ribose polymerase in BCR/ABL1-positive cells

Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1

Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy

Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1T315I and BCR-ABL1T315I-E255K

Hochschulschrift

The role of proteostasis in BCR-ABL1-positive acute lymphoblastic leukemia

Hochschulschrift

Pre-B cell receptor signaling prevents malignant transformation by BCR-ABL1

BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro

Hochschulschrift

Genomische BCR-ABL1-Bruchpunkte bei kindlichen Leukämien

The BCR::ABL1 tyrosine kinase inhibitors ponatinib and nilotinib differentially affect endothelial angiogenesis and signalling

BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene

FISH mapping of Philadelphia negative BCR/ABL1 positive CML

Approach to Diagnosis of BCR::ABL1-Negative Myeloproliferative Neoplasms

Targeting Poly(ADP)ribose polymerase in BCR/ABL1-positive cells

Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1

Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy

Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1T315I and BCR-ABL1T315I-E255K

Hochschulschrift

The role of proteostasis in BCR-ABL1-positive acute lymphoblastic leukemia

Hochschulschrift

Pre-B cell receptor signaling prevents malignant transformation by BCR-ABL1

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: a safety analysis of the FDA adverse event reporting system

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro

Genomische BCR-ABL1-Bruchpunkte bei kindlichen Leukämien

The BCR::ABL1 tyrosine kinase inhibitors ponatinib and nilotinib differentially affect endothelial angiogenesis and signalling

BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene

FISH mapping of Philadelphia negative BCR/ABL1 positive CML

Approach to Diagnosis of BCR::ABL1-Negative Myeloproliferative Neoplasms

Targeting Poly(ADP)ribose polymerase in BCR/ABL1-positive cells

Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1

Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy

Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1T315I and BCR-ABL1T315I-E255K

The role of proteostasis in BCR-ABL1-positive acute lymphoblastic leukemia

Pre-B cell receptor signaling prevents malignant transformation by BCR-ABL1

BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro

Genomische BCR-ABL1-Bruchpunkte bei kindlichen Leukämien

The BCR::ABL1 tyrosine kinase inhibitors ponatinib and nilotinib differentially affect endothelial angiogenesis and signalling

BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene

FISH mapping of Philadelphia negative BCR/ABL1 positive CML

Approach to Diagnosis of BCR::ABL1-Negative Myeloproliferative Neoplasms

Targeting Poly(ADP)ribose polymerase in BCR/ABL1-positive cells

Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1

Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy

Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1T315I and BCR-ABL1T315I-E255K

The role of proteostasis in BCR-ABL1-positive acute lymphoblastic leukemia

Pre-B cell receptor signaling prevents malignant transformation by BCR-ABL1

BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro

Genomische BCR-ABL1-Bruchpunkte bei kindlichen Leukämien

The BCR::ABL1 tyrosine kinase inhibitors ponatinib and nilotinib differentially affect endothelial angiogenesis and signalling

BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene

FISH mapping of Philadelphia negative BCR/ABL1 positive CML

Approach to Diagnosis of BCR::ABL1-Negative Myeloproliferative Neoplasms

Targeting Poly(ADP)ribose polymerase in BCR/ABL1-positive cells

Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1

Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy

Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1T315I and BCR-ABL1T315I-E255K

The role of proteostasis in BCR-ABL1-positive acute lymphoblastic leukemia

Pre-B cell receptor signaling prevents malignant transformation by BCR-ABL1

Related objects

Reset password